1. ALLA AKTIER
  2. NYHETER
  3. CELLAVISION

CellaVision

Nyheter CellaVision Nyheter alla bolag

Mixed Regional Performance Sales Peak in APAC

MAR

Organic sales growth:
Q4, 2024: -7% (29)

EBITDA margin:
Q4, 2024: 33% (36)

October 1 – December 31, 2024

  • Net sales decreased by 7% (+32) to SEK 187 m (201).
  • Sales decreased organically by 7% (+29), currency effect 0% (3).
  • EBITDA amounted to SEK 61 m (73).
  • EBITDA margin amounted to 33% (36).
  • Profit before tax amounted to SEK 51 m (63).
  • Earnings per share before and after dilution amounted to SEK 1.72 (2.11).
  • Cash flow from operating activities amounted to SEK 46 m (76).
  • The Board of Directors proposes a dividend of SEK 2.50 per share for 2024 (2.25).

Contact

Helena Raihle
Corporate Communications & Investor Relations
Tel: + 46 70 822 70 93
www.cellavision.com
helena.raihle@cellavision.com

About Us

CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. These analyses play a vital role in swift and accurate disease diagnoses, particularly in cases of infections and serious cancer diseases. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company´s 12 local market support organizations covering more than 40 countries. In 2023, sales were SEK 677 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

This information is information that CellaVision is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-02-06 07:20 CET.

Attachments

Interim Report Q4 2024

Datum 2025-02-06, kl 07:20
Källa MFN
Bifogade filer
Interim Report Q4 2024
Affiliate
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet